



COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

DRAFT

LIST OF REFERENCES FOR ASSESSMENT OF:

**Echinaceae purpureae herba
Echinacea purpurea (L.) Moench
(purple coneflower herb)**

The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Articles marked by asterisk (*) were available to the rapporteur only in the form of abstract.

- Baetgen D (1984) Erfolge in der Keuschhusten-behandlung mit Echinacin. Therapiewoche 34: 5115-9.
- Baetgen D (1988) Behandlung der akuten Bronchitix im Kindesalter – Praxisstudie mit einem Immunstimulans aus *Echinacea purpurea*. Pädiatrie 1: 66-70.
- Barnes J, Anderson LA, Gibbons S, Phillipson JD. (2005) *Echinacea* species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol.; 57(8):929-54. *
- Barrett B, Vohmann M, Calabrese C. (1999) *Echinacea* for upper respiratory infection. J Fam Pract. 48(8): 628-35.
- Barrett B. (2003) Medicinal properties of *Echinacea*: a critical review. Phytomedicine 10(1): 66-86.
- Barrett B. (2004) Efficacy and safety of *Echinacea* in treating upper respiratory tract infections in children: a randomized controlled trial. J Pediatr. 145(1): 135-6.
- Barrett BP, Brown RL, Locken K, Maberry R, Bobula JA, D'Alessio D. (2002) Treatment of the common cold with unrefined *Echinacea*. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 137(12): 939-46.
- Bauer R, Jurcic K, Puhlmann J, Wagner H (1988a) Immunologic in vivo and in vitro studies on *Echinacea* extracts. Arzneimittel Forschung 38: 276-81.
- Bauer R, Remiger P, Jurcic K, Wagner H (1989) Beeinflussung der Phagozytose-Aktivitat durch *Echinacea*-Extrakte. Zeitschrift für Phytotherapie 10: 43-8.
- Bauer R, Remiger P, Wagner H (1988b). *Echinacea*. Comparative TLC and HPLC analysis of herbal drugs from *Echinacea purpurea*, *E. pallida* and *E. angustifolia*. Part 3. Dtsch. Apoth. Ztg. 128: 174-180.
- Bauer R, Khan IA, Wagner H.(1988c) TLC and HPLC Analysis of *Echinacea pallida* and *E. Angustifolia* Roots. Planta Medica 1988; 54:426-30.
- Bauer R. (2002) New knowledge regarding the effect and effectiveness of *Echinacea purpurea* extracts. Wien Med Wochenschr 152(15-16): 407-11.

- Binns SE, Purgina B, Bergeron C, Smith ML, Ball L, Baum BR, Arnason JT. (2000) Light-mediated antifungal activity of *Echinacea* extracts. *Planta Med* 66(3): 241-4.
- Blumenthal M. (2004) *Echinacea* trial. *Altern Ther Health Med*. 10(2): 12-4.
- Bourne LC; Rice-Evans C (1998) Bioavailability of ferulic acid. *Biochemical and biophysical research communications* 253: 222-7.
- Brinkeborn RM, Shah DV, Degenring FH. (1999) Echinaforce and other *Echinacea* fresh plant preparations in the treatment of the common cold. A randomized, placebo controlled, double-blind clinical trial. *Phytomedicine* 6(1): 1-6.
- Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. (1997) *Echinacea*-induced cytokine production by human macrophages. *Int J Immunopharmacol*. 19(7): 371-9.
- Cheminat A, Zawatzky R, Becker H, Bruillard R (1988) Caffeoyle conjugates from *Echinacea* species: structures and biological activity *Phytochemistry* 27: 2787-94.
- Chow G, Johns T, Miller SC. (2006) Dietary *Echinacea purpurea* during murine pregnancy: effect on maternal hemopoiesis and fetal growth. *Biol Neonate*. 2006;89(2):133-8.
- Clifford LJ, Nair MG, Rana J, Dewitt DL. (2002) Bioactivity of alkaloids isolated from *Echinacea purpurea* (L.) Moench. *Phytomedicine* 9(3): 249-53.
- Currier NL, Miller SC. (2000) Natural killer cells from aging mice treated with extracts from *Echinacea purpurea* are quantitatively and functionally rejuvenated. *Exp Gerontol*. 35(5): 627-39.
- Dietz B, Heilmann J, Bauer R (2001) Absorption of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides after oral application of *Echinacea purpurea* tincture. *Planta Med*. 67: 863-4.
- Dorsch W (1996) Klinische Anwendung von Extrakt aus *Echinacea purpurea* oder *Echinacea pallida*. *Zeitschrift für ärztliche Fortbildung* 90: 117-22.
- Dorsch W, Loew D, Meyer-Buchtela E, Schilcher H. (2002) Kinderdosierungen von Phytopharmaka, Kooperation Phytopharmaka.
- ESCOPE (2003) European Scientific Cooperative on Phytotherapy monographs on the medicinal uses of plant drugs, *Echinaceae purpureae herba* (purple coneflower herb), 129-36.
- Firenzuoli F, Gori L. (2004) *Echinacea* for treating colds in children. *JAMA* 291(11): 1323-4.
- Foster S. (1996) The Purple Coneflowers. American Botanical Council, <http://www.herbalgram.org/>
- Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G. (2000) Pregnancy outcome following gestational exposure to *Echinacea*: a prospective controlled study. *Arch Intern Med*. 160(20): 3141-3.
- Gan XH, Zhang L, Heber D, Bonavida B. (2003) Mechanism of activation of human peripheral blood NK cells at the single cell level by *Echinacea* water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. *Int Immunopharmacol*. 3(6): 811-24.
- Gertsch J, Schoop R, Kuenzle U, Suter A (2004) *Echinacea* alkylamides modulate TNF- α gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. *FEBS Letters* 577, 3, 563-9.
- Giancaspro G (2004): *Echinacea purpurea* Aerial Parts, *Pharmacopeial Forum* 30: 557-60.
- Giles JT, Palat CT 3rd, Chien SH, Chang ZG, Kennedy DT. (2000) Evaluation of *Echinacea* for treatment of the common cold. *Pharmacotherapy* 20(6): 690-7.
- Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. (2003) *Echinacea* and truth in labelling. *Arch Intern Med*.;163(6):699-704. *
- Goel V, Chang C, Slama JV, Barton R, Bauer R, Gahler R, Basu TK. (2002) Alkylamides of *Echinacea purpurea* stimulate alveolar macrophage function in normal rats. *Int Immunopharmacol*. 2(2-3): 381-7.

- Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, Basu TK. (2004) Efficacy of a standardized *Echinacea* preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. *J Clin Pharm Ther.* 29(1): 75-83.
- Goel V, Lovlin R, Chang C, Slama JV, Barton R, Gahler R, Bauer R, Goonewardene L, Basu TK. (2005) A proprietary extract from the *Echinacea* plant (*Echinacea purpurea*) enhances systemic immune response during a common cold. *Phytother Res.*; 19(8):689-94. *
- Gotti R, Pomponio R, Bertucci C, Cavrini V (2002) Simultaneous analysis of the lipophilic and hydrophilic markers of *Echinacea* plant extracts by capillary electrophoresis. *Journal of Separation Science* 25, 15-17, 1079 – 86.
- Gorski JC, Huang S-M, Pinto A, et al. (2004) The effect of *Echinacea* (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther.* 2004;75: 89-100.
- Grimm W, Muller HH. (1999) A randomized controlled trial of the effect of fluid extract of *Echinacea purpurea* on the incidence and severity of colds and respiratory infections. *Am J Med.* 106(2):138-43.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A (2004) In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: *Citrus aurantium*, *Echinacea purpurea*, milk thistle, and saw palmetto. *Clin Pharmacol Ther.* 2004 Nov;76(5):428-40. *
- HagerROM 2004: Hagers handbuch der Drogen und Arzneistoffe, CD-ROM version 5.1.
- Heinen-Kammerer T, Holtmannspotter C, Schnabel S, Motzkat K, Kiencke P, Rychlik R. (2005) Effectiveness of echinacin in therapy of chronic recurrent respiratory disease *Gesundheitswesen.*; 67(4):296-301. *
- Hoheisel O, Sandberg M, Bertram S, Bulitta M, Schafer M. (1997) Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. *European Journal of Clinical Research* 9: 261-8.
- Hostettmann K. (2003) History of a plant: the example of *Echinacea* Forsch. *Komplementarmed Klass Naturheilkd.*;10 Suppl 1:9-12. *
- Huntley A, Coon JT, Ernst E (2005) The safety of herbal medicinal products derived from *Echinacea* species. *Drug Safety*; 28(5):387-400. *
- Izzo AA, Ernst E. (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs.* 61(15): 2163-75.
- Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle HP, Heilmann J: Transport of Alkamides from *Echinacea* Species through Caco-2 Monolayers¹. *Planta Med.* 2000; 68: 469-71.
- Kemp DE, Franco KN (2002) Possible leukopenia associated with long-term use of *Echinacea*. *J Am Board Fam Pract.* 15(5): 417-9.
- Kim L, Wollner D, Anderson P, Brammer D. (2004) *Echinacea* for treating colds in children. *JAMA* 291(11): 1323.
- Kinkel HJ, Plate M, Tullner HU (1984) Effect of Echinacin ointment in healing of skin lesions. *Medizinische Klinik* 79; 580-3.
- Kommission E, (1989) *Aufbereitungsmonographie Echinacea purpurea* Kommission E vom 2.3.1989.
- Koenig K, Roehr CC. Does treatment with *Echinacea purpurea* effectively shorten the course of upper respiratory tract infections in children? *Arch Dis Child.* 2006 Jun;91(6):535-7.
- Kreft S (2005) Cichoric acid content and biomass production of *Echinacea purpurea* plants cultivated in Slovenia. *Pharmaceutical Biology* 43 (8): 662-5.
- Le Tourneau M. (2004) *Echinacea* fails to show efficacy in treating colds in a pediatric population. *Altern Ther Health Med.* 10(1): 16.
- Lee AN, Werth VP. (2004) Activation of autoimmunity following use of immunostimulatory herbal supplements. *Arch Dermatol.* 140(6): 723-.

- Lenk W (1989) Acute toxicity of various polysaccharides from *Echinacea purpurea* in the mouse. *Zeitschrift für Phytotherapie* 10: 49-51.
- Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. (2006) *Echinacea* for preventing and treating the common cold. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD000530.pub2.
- Lindenmuth GF, Lindenmuth EB. The efficacy of echinacea compound herbal tea preparation on the severity and duration of upper respiratory and flu symptoms: a randomized, double-blind placebo-controlled study. *J Altern Complement Med.* 2000 Aug;6(4):327-34. *
- Logan JL, Ahmed J. (2003) Critical hypokalemic renal tubular acidosis due to Sjogren's syndrome: association with the purported immune stimulant echinacea. *Clin Rheumatol.* 2003;22(2): 158-9.
- Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohmann-Matthes ML. (1989) Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of *Echinacea purpurea*. *J Natl Cancer Inst.* 81(9): 669-75.
- Maffei Facino R. (1995) Echinacoside and caffeoyl conjugates protect collagen from free radical-induced degradation: a potential use of *Echinacea* extracts in the prevention of skin photocamage. *Planta Med;* 61: 510-4.
- Manček B, Kreft S (2005) Determination of cichoric acid content in dried press juice of purple coneflower (*Echinacea purpurea*) with capillary electrophoresis. *Talanta* 66 (5): 1094-7.
- Matthias A, Blanchfield JT, Penman KG, Toth I, Lang CS, De Voss JJ, Lehmann RP. (2004) Permeability studies of alkylamides and caffeic acid conjugates from *Echinacea* using a Caco-2 cell monolayer model. *J Clin Pharm Ther.* 29(1): 7-13.
- Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP. (2005a) Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. *Life Sci.* 2005 Sep 2;77(16):2018-29.
- Matthias A, Gillam EM, Penman KG, Matovic NJ, Bone KM, De Voss JJ, Lehmann RP. (2005b) Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes. *Chem Biol Interact.* 2005 Jun 30;155(1-2):62-70.
- Melchart D, Clemm C, Weber B, Draczynski T, Worku F, Linde K, Weidenhammer W, Wagner H, Saller R. (2002) Polysaccharides isolated from *Echinacea purpurea* herba cell cultures to counteract undesired effects of chemotherapy--a pilot study. *Phytother Res.;* 16(2):138-42. *
- Melchart D, Linde K, Worku F, Bauer R, Wagner H. (1994) Immunomodulation with *Echinacea* – a systematic review of controlled clinical trials *Phytomedicine* 1: 245-54.
- Mengs U, Clare CB, Poiley JA (1991) Toxicity of *Echinacea purpurea* - Acute, subacute and genotoxicity studies. *Arzneimittel Forschung* 41: 1076-88.
- Merali S, Binns S, Paulin-Levasseur M, Ficker C, Smith M, Baum B, Brovelli E, Arnason JT (2003) Antifungal and Anti-inflammatory Activity of the Genus *Echinacea*. *Pharmaceutical Biology (Formerly International Journal of Pharmacognosy)* 41: 412-20.
- Mishima S, Saito K, Maruyama H, Inoue M, Yamashita T, Ishida T, Gu Y. (2004) Antioxidant and immuno-enhancing effects of *Echinacea purpurea*. *Biol Pharm Bull.* 27(7):1004-9.
- Mullins RJ. (1998) Echinacea-associated anaphylaxis. *Med J Aust.* 16;168(4):170-1. *
- Mullins RJ, Heddle R. (2002) Adverse reactions associated with *Echinacea*: the Australian experience. *Ann Allergy Asthma Immunol.* 88(1): 42-51.
- Nordeng H, Havnen GC. (2004) Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. *Pharmacoepidemiol Drug Saf.* 13(6): 371-80.
- Ondrizek RR, Chan PJ, Patton WC, King A. (1999) Inhibition of human sperm motility by specific herbs used in alternative medicine. *J Assist Reprod Genet.* 16(2): 87-91.
- Orinda D, Diederich J, Wacker A (1973) Antiviral activity of compounds of *Echinacea purpurea*. *Arzneimittel-Forschung (Drug Research)* 23: 1119-20.

- Parnam MJ (1996) Benefit-risk assessment of the squeezed sap of the purple coneflower (*Echinacea purpurea*) for long term oral immunostimulation. *Phytotherapy* 1996; 3: 95-102.
- Pasco D, Pugh ND, Khan I, Moraes R (2005) Immunostimulatory agents in botanicals, US patent #20050002962.
- Pellati F, Benvenuti S, Magro L, Melegari M, Soragni F. (2004) Analysis of phenolic compounds and radical scavenging activity of *Echinacea* spp. *J Pharm Biomed Anal.* 16; 35(2):289-301.
- Perri D, Dugoua JJ, Mills E, Koren G. Safety and efficacy of echinacea (*Echinacea angustifolia*, *E. purpurea* and *E. pallida*) during pregnancy and lactation. *Can J Clin Pharmacol.* 2006 Fall; 13(3):262-7.
- Pietta P, Mauri P, Bauer R (1998). MEKC Analysis of different *Echinacea* species. *Planta Med.* 64: 649-52.
- Proksch A, Wagner H (1987) Structural analysis of a 4-O-methylglucuronarabinoxylan with immunostimulating activity from *Echinacea purpurea*. *Phytochemistry* 26: 1989-93.
- Pugh ND, Balachandran P, Lata H, Dayan FE, Joshi V, Bedir E, Makino T, Moraes R, Khan I, Pasco DS (2005) Melanin: dietary mucosal immune modulator from *Echinacea* and other botanical supplements. *Int Immunopharmacol.* 5(4): 637-47.
- Randolph RK, Gellenbeck K, Stonebrook K, Brovelli E, Qian Y, Bankaitis-Davis D, Cheronis J. (2003) Regulation of human immune gene expression as influenced by a commercial blended *Echinacea* product: preliminary studies. *Exp. Biol. Med.* 228: 1051-6.
- Reisch J, Spitzner W, Schulte KE (1967) The problem of the microbiological activity of simple acetylene compounds. *Arzneimittel Forschung* 17: 816-25.
- Rininger JA, Kickner S, Chigurupati P, McLean A, Franck Z. (2000) Immunopharmacological activity of *Echinacea* preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. *J Leukoc Biol.* 68(4): 503-10.
- Roesler J, Steinmuller C, Kiderlen A, Emmendorffer A, Wagner H, Lohmann-Matthes ML. (1991) Application of purified polysaccharides from cell cultures of the plant *Echinacea purpurea* to mice mediates protection against systemic infections with *Listeria monocytogenes* and *Candida albicans*. *Int J Immunopharmacol.* 13(1): 27-37.
- Schimmer O, Abel G, Behninger C (1989) Investigations on the genotoxic potency of a neutral polysaccharide from *Echinacea* cell cultures in cultured human Lymphocytes. *Zeitschrift für Phytotherapie* 10: 39-42.
- Schulte KE, Rücker G, Boehme R (1967) Polyacetylenes as compounds of the roots of burs. *Arzneimittel Forschung* 17: 829-33.
- Schulte KE, Rücker G, Perlick J (1967) The presence of polyacetylene compounds in *Echinacea purpurea* and *Echinacea angustifolia*. *Arzneimittel Forschung* 17: 825-29.
- Schulten B, Bulitta M, Ballering-Bruhl B, Koster U, Schafer M. (2001). Efficacy of *Echinacea purpurea* in patients with a common cold. A placebo-controlled, randomised, double-blind clinical trial. *Arzneimittelforschung* 51(7): 563-68.
- Schwarz E, Metzler J, Diedrich JP, Freudenstein J, Bode C, Bode JC. (2002) Oral administration of freshly expressed juice of *Echinacea purpurea* herbs fail to stimulate the nonspecific immune response in healthy young men: results of a double-blind, placebo-controlled crossover study. *J Immunother.* 25(5): 413-20.
- Skwarek T, Tynecka Z, Glowniak K, Lutostanska E (1996) *Echinacea* – inducer of interferons. *Herba Polonica* 42: 110-7.
- Soon SL, Crawford RI. (2001) Recurrent erythema nodosum associated with Echinacea herbal therapy. *J Am Acad Dermatol.* 2001;44(2): 298-9. *
- Sperber SJ, Shah LP, Gilbert RD, Ritchey TW, Monto AS. (2004) *Echinacea purpurea* for prevention of experimental rhinovirus colds. *Clin Infect Dis.* 38(10): 1367-71.

- Steinmuller C, Roesler J, Grottrup E, Franke G, Wagner H, Lohmann-Matthes ML. (1993) Polysaccharides isolated from plant cell cultures of *Echinacea purpurea* enhance the resistance of immunosuppressed mice against systemic infections with *Candida albicans* and *Listeria monocytogenes*. *Int J Immunopharmacol.* 15(5): 605-14.
- Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML. (1984) Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant *Echinacea purpurea*. *Infect Immun.* 46(3): 845-9.
- Stotzem CD, Hungerland U, Mengs U (1992) Influence of *Echinacea purpurea* on the phagocytosis of human granulocytes *Med Sci Res* 20: 719-20.
- Taylor JA, Weber W, Calabrese C. (2004) *Echinacea* for treating colds in children. *JAMA* 291(11): 1324.
- Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C. (2003) Efficacy and safety of *Echinacea* in treating upper respiratory tract infections in children: a randomized controlled trial. *JAMA* 290(21): 2824-30.
- Tünnerhoff FK, Schwabe HK (1956) Studies in human beings and animals on the influence of *Echinacea* extracts on the formation of connective tissue following the implantation of fibrin. *Arzneimittelforschung* 6: 330-4.
- Turner RB, Riker DK, Gangemi JD. (2000) Ineffectiveness of *Echinacea* for prevention of experimental rhinovirus colds. *Antimicrob Agents Chemother.* 44(6): 1708-9.
- Uang YS; Hsu KY (1997) A dose-dependent pharmacokinetic study on caffeic acid in rabbits after intravenous administration. *Biopharmaceutics and drug disposition* 18: 727-36.
- Vonau B, Chard S, Mandalia S, Wilkinson D, Barton SE. (2001) Does the extract of the plant *Echinacea purpurea* influence the clinical course of recurrent genital herpes? *Int J STD AIDS.*; 12(3):154-8. *
- Wacker A, Hilbig W (1978) Virus-inhibition by *Echinacea purpurea*. *Planta medica* 33: 89-102.
- Wagner H, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, Stuppner H, Jurcic K, Le Turdu M, Fang JN. (1985) Immunostimulating action of polysaccharides (heteroglycans) from higher plants. *Arzneimittelforschung* 35(7): 1069-75.
- Wagner H, Stuppner H, Schafer W, Zenk M A (1988). Immunologically active polysaccharides of *Echinacea purpurea* cell cultures. *Phytochemistry* 27: 119-26.
- Washam C. (2004) *Echinacea* no cure-all for kids. *Environ Health Perspect.* 112(8): A466.
- Westendorf J; Czok G (1978) Pharmacokinetic of ¹⁴C labelled derivatives of cinnamic acid on rats. *Zeitschrift für Ernährungswissenschaft* 17: 26-36
- WHO (1999): WHO monographs on selected medicinal plants, Vol. 1, WHO Geneva 1999, 136-144.
- Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, Bauer R. (2005) Bioavailability and pharmacokinetics of alkamides from the roots of *Echinacea angustifolia* in humans. *J Clin Pharmacol.*; 45(6):683-9. *
- Yale SH, Liu K. (2004) *Echinacea purpurea* therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. *Arch Intern Med.* 2004 Jun 14;164(11):1237-41.
- Yale SH, Glurich I. (2006) Analysis of the inhibitory potential of Ginkgo biloba, *Echinacea purpurea*, and *Serenoa repens* on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. *J Altern Complement Med.* 2005 Jun;11(3):433-9. *
- Zoutewelle G, Van Wijk R (1990) Effects of *Echinacea purpurea* extracts on fibroblast populated collagen lattice contraction. *Phytotherapy Research* 4: 77-81.